| Autor: |
A, Livneh, D, Zemer, P, Langevitz, A, Laor, E, Sohar, M, Pras |
| Rok vydání: |
1994 |
| Předmět: |
|
| Zdroj: |
Arthritis and rheumatism. 37(12) |
| ISSN: |
0004-3591 |
| Popis: |
To elucidate factors possibly influencing the outcome of colchicine therapy in patients with amyloidosis of familial Mediterranean fever (FMF).Retrospective analysis of data abstracted from the charts of all 68 FMF patients with amyloidosis who presented during the study period (1974-1992) with proteinuria (or = 0.5 gm/24 hours) and creatinine valuesor = 2.5 mg/dl, received colchicine, and were followed up foror = 5 years.At the end of the study period, kidney disease had worsened in 31 patients and remained stable in 22. Proteinuria had regressed in 15 patients. Deterioration was related to initial serum creatinine valuesor = 1.5 mg/dl (P0.01) and to mean colchicine dosageor = 1.5 mg/day (P0.001). The 3 groups were comparable in terms of initial urinary protein levels, duration of proteinuria, presence of hypertension, occurrence of febrile attacks, sex distribution, and proportion of non-compliant patients.The therapeutic dosage of colchicine for amyloidosis of FMF is1.5 mg/day. This dosage is effective only in patients with initial serum creatinine levels1.5 mg/dl. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text